Comparison of 10 noninvasive models for predicting overall survival in patients with intermediate-stage hepatocellular carcinoma

被引:4
|
作者
Hsu, Wei-Fan [1 ,2 ,3 ,9 ]
Chang, Kai-Chih [1 ]
Chen, Te-Hong [4 ,9 ]
Lin, Chien-Hung [5 ,9 ]
Lin, Ying-Chun [6 ,9 ]
Tsai, Ming-Hung [7 ,9 ]
Chen, Pei-Yu [8 ,9 ]
Wang, Hung-Wei [1 ,3 ,9 ]
Chu, Chia-Sheng [1 ,9 ]
Peng, Cheng-Yuan [1 ,3 ,9 ]
机构
[1] China Med Univ Hosp, Ctr Digest Med, Dept Internal Med, 2 Der Yuh Rd, Taichung 40447, Taiwan
[2] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan
[3] China Med Univ, Sch Med, Taichung, Taiwan
[4] China Med Univ Hosp, Dept Surg, Taichung, Taiwan
[5] China Med Univ Hosp, Dept Radiol, Taichung, Taiwan
[6] China Med Univ Hosp, Dept Radiat Oncol, Taichung, Taiwan
[7] China Med Univ Hosp, Div Hematol & Oncol, Dept Internal Med, Taichung, Taiwan
[8] China Med Univ Hosp, Dept Pathol, Taichung, Taiwan
[9] China Med Univ Hosp, Liver Canc Team, Taichung, Taiwan
关键词
albumin-bilirubin (ALBI) grade; intermediate-stage hepatocellular carcinoma; Lok grade; noninvasive model; SIGNIFICANT FIBROSIS; LIVER-FUNCTION; HEPATITIS-B; CIRRHOSIS; INDEX; ALBI; SUBCLASSIFICATION; CRITERIA; PROPOSAL; DISEASE;
D O I
10.1097/MD.0000000000027000
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Intermediate-stage hepatocellular carcinoma (HCC) is heterogeneous in terms of tumor size, number, and effects on liver function. Various noninvasive models have been proposed to assess functional hepatic reserve or fibrosis severity in patients with HCC. This study assessed the feasibility of 10 noninvasive models and compared their prognostic ability for patients with intermediate-stage HCC. This study retrospectively enrolled 493 patients with intermediate-stage HCC who received treatment at China Medical University Hospital from January 2012 to November 2018. Demographic data, clinical features, and factors associated with overall survival (OS) were recorded at baseline. Receiver-operating characteristic curve analysis and the DeLong method were respectively employed to evaluate and compare the models' OS prediction performance. Of the 493 patients, 373 (75.7%) were male, and 275 (55.8%) had liver cirrhosis (LC). The median age was 64 years (interquartile range: 55-72). Most patients had tumor volume <= 50% (n = 424, 86.0%), and the maximum tumor size was 6.0 (4.0-8.5) cm. The median alpha-fetoprotein was 36.25 (6.13-552.91) ng/mL. The patients underwent transarterial chemoembolization (TACE, n = 349) or surgery (n = 144). The median follow-up period was 26.07 (9.77-48.27) months. Across the 10 models, the albumin-bilirubin (ALBI) score had the highest area under the receiver operating characteristic curve (AUROC) (0.644, 95% confidence interval: 0.595-0.693) in all patients. In subgroup analyses, the Lok index, platelet-albumin-bilirubin score, ALBI score, and Lok index had the highest AUROC values in patients without cirrhosis, with cirrhosis, undergoing TACE, and undergoing surgery, respectively. Multivariate Cox regression analysis revealed that independent predictors of longer OS were ALBI grade 1 in all patients, patients with LC, and patients undergoing TACE and Lok index grade 1 in patients without LC and patients undergoing surgery. Among the 10 noninvasive models, ALBI score exhibited the highest diagnostic value in predicting OS for all patients, patients with cirrhosis, and those undergoing TACE, and Lok index grade exhibited the highest diagnostic value in predicting OS in patients without cirrhosis and those undergoing surgery.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation
    Ni, Jia-yan
    Fang, Zhu-ting
    Sun, Hong-liang
    An, Chao
    Huang, Zhi-mei
    Zhang, Tian-qi
    Jiang, Xiong-ying
    Chen, Yao-ting
    Xu, Lin-feng
    Huang, Jin-hua
    EUROPEAN RADIOLOGY, 2020, 30 (04) : 2377 - 2390
  • [32] Hepatic Resection Provides Survival Benefit for Selected Intermediate-Stage (BCLC-B) Hepatocellular Carcinoma Patients
    Zhang Zhaohui
    Shen Shunli
    Chen Bin
    Li Shaoqiang
    Hua Yunpeng
    Kuang Ming
    Liang Lijian
    Peng Bao Gang
    CANCER RESEARCH AND TREATMENT, 2019, 51 (01): : 65 - 72
  • [33] Early treatment response to transcatheter arterial chemoembolization is associated with time to the development of extrahepatic metastasis and overall survival in intermediate-stage hepatocellular carcinoma
    Lee, Sung Won
    Lee, Hae Lim
    Han, Nam Ik
    Jang, Jeong Won
    Bae, Si Hyun
    Choi, Jong Young
    Yoon, Seung Kew
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (01) : 81 - 88
  • [34] Early treatment response to transcatheter arterial chemoembolization is associated with time to the development of extrahepatic metastasis and overall survival in intermediate-stage hepatocellular carcinoma
    Sung Won Lee
    Hae Lim Lee
    Nam Ik Han
    Jeong Won Jang
    Si Hyun Bae
    Jong Young Choi
    Seung Kew Yoon
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 81 - 88
  • [35] When to Perform Hepatic Resection for Intermediate-Stage Hepatocellular Carcinoma
    Cucchetti, Alessandro
    Djulbegovic, Benjamin
    Tsalatsanis, Athanasios
    Vitale, Alessandro
    Hozo, Iztok
    Piscaglia, Fabio
    Cescon, Matteo
    Ercolani, Giorgio
    Tuci, Francesco
    Cillo, Umberto
    Pinna, Antonio Daniele
    HEPATOLOGY, 2015, 61 (03) : 905 - 914
  • [36] Application of radiofrequency ablation for the treatment of intermediate-stage hepatocellular carcinoma
    Nouso, Kazuhiro
    Kariyama, Kazuya
    Nakamura, Shinichiro
    Oonishi, Ayano
    Wakuta, Akiko
    Oyama, Atsushi
    Ako, Soichiro
    Dohi, Chihiro
    Wada, Nozomu
    Morimoto, Yuki
    Takeuchi, Yasuto
    Kuwaki, Kenji
    Onishi, Hideki
    Ikeda, Fusao
    Shiraha, Hidenori
    Takaki, Akinobu
    Okada, Hiroyuki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 (03) : 695 - 700
  • [37] Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma
    Rizzo, Alessandro
    Dalia Ricci, Angela
    Brandi, Giovanni
    ONCOLOGIST, 2022, 27 (12): : E976 - E976
  • [38] Comparison of radiofrequency ablation with surgical resection in patients with intermediate-stage hepatocellular carcinoma: A single-center experience
    Tseng, Y. C.
    Lin, M. C.
    Chen, C. T.
    Chen, P. J.
    Lin, H. H.
    Huange, H. H.
    Huang, T. Y.
    Hsieh, T. Y.
    Chang, W. K.
    Shih, Y. L.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 334 - 334
  • [39] Potential new treatment approach for intermediate-stage hepatocellular carcinoma
    Nierengarten, Mary Beth
    CANCER, 2025, 131 (02)
  • [40] Effectiveness of sorafenib in treating intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization
    Ashour, Reham
    Rewisha, Eman
    Rady, Mohamed A. K. L.
    Elkhadry, Sally Waheed
    Abdelhalim, Heba
    Atef, Mohamed
    BMC CANCER, 2024, 24 (01)